Sinovac Reports Preliminary Top-Line Results from Phase III Clinical Trial for EV71 Vaccine Candidate Against Hand, Foot and Mouth Disease

- Unblinded Phase III Preliminary Results Demonstrate Vaccine Efficacy Rate of 95.4%

Sinovac Biotech Ltd. (SVA), a leading provider of vaccines in China, announced today preliminary top-line data from its Phase III clinical trial assessing the efficacy, immunogenicity and safety of the Company's proprietary Enterovirus 71 ("EV71") vaccine against hand, foot and mouth disease ("HFMD").

The primary objective of the study was to evaluate the efficacy of the EV71 vaccine in the prevention of HFMD caused by EV71 in infants of 6 to 35 months old. The preliminary Phase III data showed that Sinovac's EV71 vaccine was 95.4% (95% CI: 87.5%, 98.3%) efficacious against HFMD caused by EV71.

PharmAthene To Host Year-End 2012 Conference Call And Webcast On Wednesday, March 13, 2013

PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial and operational results for the year ended 2012 will be released on Wednesday, March 13, 2013.

PharmAthene management will host a conference call to discuss the Company's year-end financial and operational results beginning at 4:30 p.m. Eastern Time on Wednesday, March 13, 2013 and is expected to last approximately 30 minutes. The dial-in number within the United States is 866-788-0544.  The dial-in number for international callers is 857-350-1682.  The participant passcode is 83184036.

CEO of ARCA biopharma to Speak on Changing Paradigms in Drug Development at ACC.13 Conference on March 10, 2013

ARCA biopharma, Inc. (ABIO), a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation and other cardiovascular diseases, announced today that Dr. Michael Bristow, President and Chief Executive Officer, will present “The Changing Paradigms in Drug Development” at conference session “Joint Symposium of the Heart Failure Society and the American College of Cardiology II: Heart Failure Care in the Era of Health Care Reform” at the American College of Cardiology 62^nd Annual Scientific Sessions & Expo, being held March 9-11, 2013 in San Francisco, California. The conference session is scheduled on Sunday, March 10, 2013, from 12:30pm – 1:45pm Pacific.

Osiris Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results

Osiris Therapeutics, Inc. (OSIR) the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today its results for the fourth quarter and full year ended December 31, 2012.

Recent and Full Year Highlights

• Achieved world’s first approval for a stem cell drug from Health Canada to market Prochymal® (remestemcel-L) for the treatment of acute graft versus host disease (GvHD) in children.

  Published: 06 March 2013

  Written by Editor

  Nasdaq   Healthcare   Financial Results   Up on News   Interesting News  

  Read more: Osiris Therapeutics Inc ( OSIR )